NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer

• Type: Article in International Scientific Journal
• Date: 2016

Authors

Silva, MP (Author) Other; Barros Silva, JD (Author) Other; Vieira, J (Author) Other; Lisboa, S (Author) Other; Torres, L (Author) Other; Correia, C (Author) Other; Vieira Coimbra, M (Author) Other; Martins, AT (Author) Other; Carmen Jeronimo (Author) ICBAS; henrique, rmf (Author) ICBAS; Paulo, P (Author) Other; Manuel R Teixeira (Author) ICBAS

Journal

Title: Genes Chromosomes and Cancer

Vol. 55

Pages: 365-374

ISSN: 1045-2257

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 10 Citations

Scopus - 9 Citations

Other information

Authenticus ID: P-00K-6B0

DOI: 10.1002/gcc.22340

Abstract (EN): Prostate carcinomas harboring 8q gains are associated with poor clinical outcome, but the target genes of this genomic alteration remain to be unveiled. In this study, we aimed to identify potential 8q target genes associated with clinically aggressive prostate cancer (PCa) using fluorescence in situ hybridization (FISH), genome-wide mRNA expression, and protein expression analyses. Using FISH, we first characterized the relative copy number of 8q (assessed with MYC flanking probes) of a series of 50 radical prostatectomy specimens, with available global gene expression data and typed for E26 transformation specific (ETS) rearrangements, and then compared the gene expression profile of PCa subsets with and without 8q24 gain using Significance Analysis of Microarrays. In the subset of tumors with ERG fusion genes (ERG+), five genes were identified as significantly overexpressed (false discovery rate [FDR], 5%) in tumors with relative 8q24 gain, namely VN1R1, ZNF417, CDON, IKZF2, and NCOA2. Of these, only NCOA2 is located in 8q (8q13.3), showing a statistically higher mRNA expression in the subgroup with relative 8q gain, both in the ERG+ subgroup and in the whole series (P=0.000152 and P=0.008, respectively). Combining all the cases with NCOA2 overexpression, either at the mRNA or at the protein level, we identified a group of tumors with NCOA2 copy-number increase, independently of ETS status and relative 8q24 gain. Furthermore, for the first time, we detected a structural rearrangement involving NCOA2 in PCa. These findings warrant further studies with larger series to evaluate if NCOA2 relative copy-number gain presents prognostic value independently of the well-established poor prognosis associated with MYC relative copy-number gain. (c) 2016 Wiley Periodicals, Inc.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10